Intravenous versus subcutaneous EPO: Anything to do with pure red cell aplasia complication

被引：5

作者：

Chow, KM ^{[1
]}

Szeto, CC ^{[1
]}

Li, PKT ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2003年 / 41卷 / 01期

关键词：

D O I：

10.1053/ajkd.2003.50072

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：266 / 267

页数：2

共 6 条

[1] Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients [J].

Besarab, A ;

Reyes, CM ;

Hornberger, J .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (03) :439-446

[2] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[3]

Gershon SK, 2002, NEW ENGL J MED, V346, P1584

[4] European Best Practice Guidelines 9-13 -: Anaemia management [J].

Jacobs, C ;

Hörl, WH ;

Macdougall, IC ;

Valderrábano, F ;

Parrondo, I ;

Abraham, IL ;

Segner, A .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 :33-42

[5]

KLAUS GGB, 1993, CLIN ASPECTS IMMUNOL, P107

[6]

McClellan WM, 2001, AM J KIDNEY DIS, V37, part. no.

← 1 →